Table 1 Existence and numbers of additional indications
From: Lifecycle management of orphan drugs approved in Japan
Ingredient (%) | Times | |||
|---|---|---|---|---|
No additional indication | 105 (61) | 0.0 | ||
With additional indication | 68 (39) | 2.0 | ||
NonOD → OD | 34 (20) | 57 (33) | 1.7 | 2.2 |
OD → nonOD | 23 (13) | 3.0 | ||
OD → OD | 11 (6) | 1.1 | ||